AAO 2023: Paediatric myopia management is focal point for Phase III CHAMP and other trials


Analysis of data from the European Union and the United States showed low-dose, preservative-free formulation of atropine is effective in slowing myopia progression in children

A young girl with glasses sits in a classroom, cutting paper. Image credit: ©Iryna – stock.adobe.com

Analysis showed low-dose, preservative-free formulation of atropine is effective in slowing myopia progression in children. Image credit: ©Iryna – stock.adobe.com

Three new studies, including a new global study showing that low-dose atropine can help slow myopia in children, were presented at this year’s annual AAO meeting.

Darren J Bell, MD, of Medical Center Ophthalmology Associates in San Antonio, Texas, United States, is one of the investigators of the new study. The Phase III CHAMP (Childhood Atropine for Myopia Progression) clinical study was a 3 year, placebo-controlled international trial. Analysis from Bell showed low-dose, preservative-free formulation of atropine is effective in slowing progression in children aged 3 to 17, living in the US and European Union.

The children had between −0.50 D to −6.00 D spherical equivalent refraction and received daily placebo or a proprietary formulation of low-dose atropine. The proportion of responders compared with placebo was: 31.6%/21.3% (<0.50 D, P = .007), 42.8%/29.4% (<0.75 D, P = .001) and 54.8%/43% (<1.00 D, P = .006) at 3 years.

The US FDA accepted a NDA for the investigational drug used in this study, with a decision on its approval expected in January 2024.

“We found that low-dose atropine is suitable for all children with myopia, regardless of age, sex, race, iris color or baseline spherical equivalent refraction,” said Bell. “These results are a major advance for myopia management and for the kids and parents who myopia impacts.”

Other notable studies on slowing myopia in children presented at AAO include:

  • Factors Associated With Myopia Progression in Children 5 to 12 Years of Age (PO409)
    The authors conclude that younger children with greater baseline myopia should be the focus of myopia control strategies. Researchers conducted a pooled analysis of 187 children with myopia who were randomised to nightly 0.01% atropine or placebo for 2 years, followed by 6 months of no treatment. The analysis also showed that race, sex and iris color were not associated with atropine’s success rate.
  • Five-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report (PO411).
    An extension of the original LAMP trial, it followed 257 children in China for 5 years, aged 4 to 12, who were treated with higher-dose atropine, 0.05%. Researchers found that the higher dose was effective and that by year 4 and 5 follow-up, as-needed treatment could be considered for older children when their progression was stable.
Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.